The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Second primary malignancies in thyroid cancer patients
Open accessAbstract
The late health effects associated with radioiodine ((131)I) given as treatment for thyroid cancer are difficult to assess since the number of thyroid cancer patients treated at each centre is limited. The risk of second primary malignancies (SPMs) was evaluated in a European cohort of thyroid cancer patients. A common database was obtained by pooling the 2-year survivors of the three major Swedish, Italian, and French cohorts of papillary and follicular thyroid cancer patients. A time-dependent analysis using external comparison was performed. The study concerned 6841 thyroid cancer patients, diagnosed during the period 1934-1995, at a mean age of 44 years. In all, 17% were treated with external radiotherapy and 62% received (131)I. In total, 576 patients were diagnosed with a SPM. Compared to the general population of each of the three countries, an overall significantly increased risk of SPM of 27% (95% CI: 15-40) was seen in the European cohort. An increased risk of both solid tumours and leukaemias was found with increasing cumulative activity of (131)I administered, with an excess absolute risk of 14.4 solid cancers and of 0.8 leukaemias per GBq of (131)I and 10(5) person-years of follow-up. A relationship was found between (131)I administration and occurrence of bone and soft tissue, colorectal, and salivary gland cancers. These results strongly highlight the necessity to delineate the indications of (131)I treatment in thyroid cancer patients in order to restrict its use to patients in whom clinical benefits are expected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Sources and effects of ionizing radiation
(2018) · United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) Reports · doi:10.18356/f48d655d-en · Cited by 3,985
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.
Breslow, N. E., & Day, N. E. (1987) · PubMed · Cited by 1,684
Papillary and Follicular Thyroid Carcinoma
Schlumberger, M. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380506 · Cited by 1,623
Self-citationStatistical Methods in Cancer Research, Volume II: The Design and Analysis of Cohort Studies.
Cornell, R. G., Breslow, N. E., & Day, N. E. (1992) · Journal of the American Statistical Association · doi:10.2307/2290308 · Cited by 691
(1991) · Annals of the ICRP · doi:10.1016/0146-6453(91)90017-b · Cited by 565
The mammary gland iodide transporter is expressed during lactation and in breast cancer
Tazebay, U. H., Wapnir, I. L., Levy, O., Dohan, O., Zuckier, L. S., Hua Zhao, Q., Fu Deng, H., Amenta, P. S., Fineberg, S., Pestell, R. G., et al. (2000) · Nature Medicine · doi:10.1038/78630 · Cited by 493
Cancer Mortality Following Treatment for Adult Hyperthyroidism
Ron, E. (1998) · JAMA · doi:10.1001/jama.280.4.347 · Cited by 377
The Concise Handbook of Family Cancer Syndromes
Lindor, N. M., Greene, M. H., & Program, M. F. C. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1039 · Cited by 339
Mack, W. J., Preston-Martin, S., Dal Maso, L., Galanti, R., Xiang, M., Franceschi, S., Hallquist, A., Jin, F., Kolonel, L., La Vecchia, C., et al. (2003) · Cancer Causes & Control · doi:10.1023/a:1026349702909 · Cited by 296
Franklyn, J. A., Maisonneuve, P., Sheppard, M., Betteridge, J., & Boyle, P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12295-x · Cited by 243
Stratakis, C. A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.7.2037 · Cited by 214
A pooled analysis of case-control studies of thyroid cancer ¶II. Menstrual and reproductive factors
Negri, E., Maso, L. D., Ron, E., Vecchia, C. L., Mark, S. D., Preston-Martin, S., McTiernan, A., Kolonel, L., Yoshimoto, Y., Jin, F., et al. (1999) · Cancer Causes & Control · doi:10.1023/a:1008880429862 · Cited by 171
Dottorini, M. E., Lomuscio, G., Mazzucchelli, L., Vignati, A., & Colombo, L. (1995) · PubMed · Cited by 162
Self-citationVecchia, C. L., Ron, E., Franceschi, S., Maso, L. D., Mark, S. D., Chatenoud, L., Braga, C., Preston‐Martin, S., McTiernan, A., Kolonel, L. N., et al. (1999) · Cancer Causes & Control · doi:10.1023/a:1008832513932 · Cited by 144
A pooled analysis of thyroid cancer studies. V. Anthropometric factors
Maso, L. D., Vecchia, C. L., Franceschi, S., Preston‐Martin, S., Ron, E., Levi, F., Mack, W. J., Mark, S. D., McTiernan, A., Kolonel, L. N., et al. (2000) · Cancer Causes & Control · doi:10.1023/a:1008938520101 · Cited by 136
Tucker, M. A., Jd, B., & Hoffman, D. A. (1985) · PubMed · Cited by 127
The development of breast carcinoma in women with thyroid carcinoma
Chen, A. Y., Levy, L. B., Goepfert, H., Brown, B. W., Spitz, M. R., & Vassilopoulou‐Sellin, R. (2001) · Cancer · Cited by 125
Horn‐Ross, P. L., Morris, J. S., Lee, M., West, D. W., Whittemore, A. S., McDougall, I. R., Nowels, K. W., STEWART, S. L., Spate, V. L., Shiau, A., et al. (2001) · PubMed · Cited by 115
Cancer risks in thyroid cancer patients
Hall, P. N., Holm, L.-E., Lundell, G. E. F., Bjelkengren, G., Larsson, L., Lindberg, S., Tennvall, J., Wicklund, H., & Boice, J. D. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.261 · Cited by 105
Self-citationMultiple primary breast and thyroid cancer
Ron, E., Curtis, R. E., Hoffman, D. A., & Flannery, J. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.13 · Cited by 100
Thyroid Cancer after Diagnostic Administration of Iodine-131
Hall, P. N., Mattsson, A. F., & Boide, J. D. (1996) · Radiation Research · doi:10.2307/3579200 · Cited by 92
Self-citationMoolgavkar, S. H., & Venzon, D. J. (1987) · The Annals of Statistics · doi:10.1214/aos/1176350270 · Cited by 56
Hall, P. N., Holm, L., Lundell, G. E. F., & Rudén, B. ‐. (1992) · Acta Oncologica · doi:10.3109/02841869209088279 · Cited by 28
Self-citation
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
“While RAI appears to be a reasonably safe therapy, it is associated with a cumulative dose-related low risk of earlyand late-onset complications such as salivary gland damage, dental caries (397), nasolacrimal duct obstruction (398), and secondary malignancies (157,281,399,400).”
InfluentialSelf-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976
Self-citationDurante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Self-citation
Metadata
- Authors
- Rubino, C., de Vathaire, F., Dottorini, M. E., Hall, P., Schvartz, C., Couette, J. E., Dondon, M. G., Abbas, M. T., Langlois, C., & Schlumberger, M.
- Venue
- British Journal of Cancer
- Published
- 2003-10-28
- Volume
- 89
- Issue
- 9
- Pages
- 1638-1644
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2088828338
- Cited by
- 655
- References
- 27
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.